search
Back to results

Ticagrelor in Human Endotoxemia Response to Human Endotoxemia

Primary Purpose

Endotoxemia

Status
Completed
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
ticagrelor
Clopidogrel
Acetylsalicylic acid lysinate
Placebo
Sponsored by
Radboud University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Endotoxemia focused on measuring endotoxin, LPS, ticagrelor, clopidogrel, acetylsalicyclic acid, placebo

Eligibility Criteria

18 Years - 35 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Age ≥ 18 and ≤ 35 years
  • Male
  • No known current medical/psychiatric diseases

Exclusion Criteria:

  • History, signs or symptoms of any cardiovascular disease
  • History of chronic obstructive pulmonary disease (COPD) or asthma
  • History of hemorrhagic diathesis, or any other disorder associated with increased risk of bleeding
  • Previous spontaneous vagal collapse
  • Use of any medication
  • Smoking
  • Liver enzyme abnormalities (defined as ALAT and/or ASAT > twice upper limit of normality)
  • Thrombocytopenia (<150*109

    /ml) or anemia (haemoglobin < 8.0 mmol/L)

  • Any obvious disease associated with immune deficiency
  • Febrile illness in the week before the LPS challenge
  • Hypersensitivity to ticagrelor or any excipients
  • Active pathological bleeding
  • History of intracranial haemorrhage
  • History of dyspepsia
  • quantitative bleeding assessment tool (BAT) score >3 (see Appendix 1)
  • Participation in another drug trial or donation of blood 3 months prior, until 3 months after the planned LPS challenge
  • Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrioventricular block, third degree atrioventricular block or a complex bundle branch block
  • Hypertension (defined as RR systolic > 160 or RR diastolic > 90)
  • Hypotension (defined as RR systolic < 100 or RR diastolic < 50)
  • Renal impairment (defined as MDRD < 60 ml/min)

Sites / Locations

  • Intensive Care Medicine, Radboud University Nijmegen Medical Centre

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Active Comparator

Placebo Comparator

Placebo Comparator

Arm Label

Ticagrelor and acetylsalicylic acid

Clopidogrel and acetylsalicylic acid

Placebo and acetylsalicylic acid

Placebo

Arm Description

7 day treatment with ticagrelor 2x90mg after a loading dose of 180 mg and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg.

7 day treatment with clopidogrel x75 mg after a loading dose of 300 mg and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg

7 day treatment with placebo and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg

7 day treatment with 2 placebos

Outcomes

Primary Outcome Measures

concentration plasma TNFalpha (pg/ml)
measured with Luminex assay

Secondary Outcome Measures

concentration plasma IL-6 (pg/ml)
measured with Luminex assay
concentration plasma IL-8 (pg/ml)
measured with Luminex assay
concentration plasma IL-10 (pg/ml)
measured with Luminex assay
concentration plasma IL-1RA (pg/ml)
measured with Luminex assay
concentration plasma IL-1beta (pg/ml)
measured with Luminex assay
concentration plasma MCP-1(pg/ml)
measured with Luminex assay
concentration plasma MIP-1a(pg/ml)
measured with Luminex assay
concentration plasma MIP-1b(pg/ml)
concentration plasma IFNgamma(pg/ml)
measured with Luminex assay
plasma adenosine
platelet monocyte complexes
flowcytometric determination of monocytic load with platelets
platelet neutrophil complexes
flowcytometric determination of neutrophil load with platelets
platelet reactivity
ex vivo stimulation of platelets with ADP and collagen, response measured as P-selectin and fibrinogen)
monocytic tissue factor expression
tissue factor expression on monocytes as measured by flow cytometry
monocytic HLA-DR expression
as measured by flow cytometry
CD14/16 ratio
measured with flow cytometry
platelet von Willebrandfactor expression
measured with flow cytometry
VASP-P
ELISA
symptoms during endotoxin day
6 point likert scale
blood pressure
mmHg
temperature
tympanic temperature

Full Information

First Posted
November 3, 2015
Last Updated
December 14, 2015
Sponsor
Radboud University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT02612480
Brief Title
Ticagrelor in Human Endotoxemia Response to Human Endotoxemia
Official Title
The Effect of Ticagrelor on the Inflammatory Response to Human Endotoxemia
Study Type
Interventional

2. Study Status

Record Verification Date
December 2015
Overall Recruitment Status
Completed
Study Start Date
October 2015 (undefined)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
December 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Radboud University Medical Center

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Rationale: In patients suffering a myocardial infarction the P2Y12 receptor antagonists prasugrel and ticagrelor improve outcome and prognosis compared to clopidogrel. Moreover, ticagrelor lowers mortality from pulmonary infections and sepsis, which cannot solely be explained by its platelet-inhibiting effect. An effect on the inflammatory response in the setting of acute myocardial might underlie this phenomenon and if substantiated support a novel beneficial mechanism of the new the P2Y12 receptor antagonists. Objective: To study whether ticagrelor, added to acetylsalicylic acid, modulates the inflammatory response to the administration of lipopolysaccharide (LPS) in humans in vivo, and to compare this effect with the P2Y12 antagonist clopidogrel. Study design: Prospective randomized placebo-controlled trial, according to a PROBE design (prospective randomized open blinded-endpoint study). Study population: Forty healthy male volunteers aged ≥ 18 and ≤ 35 years. Intervention (if applicable): Participants will be randomized to receive either placebo (twice daily), acetylsalicylic acid (80 mg once daily, after a loading dose of 160 mg) + placebo (once daily), acetylsalicylic acid (80 mg once daily, after a loading dose of 160 mg) + ticagrelor (90 mg twice daily, after a loading dose of 180 mg) or acetylsalicylic acid (80 mg once daily, after a loading dose of 160 mg)+ clopidogrel (75 mg once daily, after a loading dose of 300mg). Main study parameters/endpoints: Endpoints: area under the curve of the proinflammatory cytokines TNF-alpha, IL6, IL-10, IL1ra IL-8, IL-1β, MCP-1 MIP-1a, MIP-1b en IFN; peak concentrations of the various cytokines; plasma concentration of HMGP1; platelet-monocyte complex formation and markers of platelet function; plasma concentration of adenosine.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endotoxemia
Keywords
endotoxin, LPS, ticagrelor, clopidogrel, acetylsalicyclic acid, placebo

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ticagrelor and acetylsalicylic acid
Arm Type
Experimental
Arm Description
7 day treatment with ticagrelor 2x90mg after a loading dose of 180 mg and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg.
Arm Title
Clopidogrel and acetylsalicylic acid
Arm Type
Active Comparator
Arm Description
7 day treatment with clopidogrel x75 mg after a loading dose of 300 mg and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg
Arm Title
Placebo and acetylsalicylic acid
Arm Type
Placebo Comparator
Arm Description
7 day treatment with placebo and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
7 day treatment with 2 placebos
Intervention Type
Drug
Intervention Name(s)
ticagrelor
Other Intervention Name(s)
brillique
Intervention Description
7 day treatment of ticagrelor 2dd90mg after a loading dose of 180mg
Intervention Type
Drug
Intervention Name(s)
Clopidogrel
Other Intervention Name(s)
Plavix
Intervention Description
7 day treatment of clopidogrel 1d75mg after a loading dose of 300mg
Intervention Type
Drug
Intervention Name(s)
Acetylsalicylic acid lysinate
Other Intervention Name(s)
Aspirin
Intervention Description
7 day treatment of acetylsalicyclic acid 1d80mg after a loading dose of 160mg
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
7 day treatment with placebo
Primary Outcome Measure Information:
Title
concentration plasma TNFalpha (pg/ml)
Description
measured with Luminex assay
Time Frame
measured after challenge with endotoxin at day 7 of medication
Secondary Outcome Measure Information:
Title
concentration plasma IL-6 (pg/ml)
Description
measured with Luminex assay
Time Frame
measured after challenge with endotoxin at day 7 of medication
Title
concentration plasma IL-8 (pg/ml)
Description
measured with Luminex assay
Time Frame
measured after challenge with endotoxin at day 7 of medication
Title
concentration plasma IL-10 (pg/ml)
Description
measured with Luminex assay
Time Frame
measured after challenge with endotoxin at day 7 of medication
Title
concentration plasma IL-1RA (pg/ml)
Description
measured with Luminex assay
Time Frame
measured after challenge with endotoxin at day 7 of medication
Title
concentration plasma IL-1beta (pg/ml)
Description
measured with Luminex assay
Time Frame
measured after challenge with endotoxin at day 7 of medication
Title
concentration plasma MCP-1(pg/ml)
Description
measured with Luminex assay
Time Frame
measured after challenge with endotoxin at day 7 of medication
Title
concentration plasma MIP-1a(pg/ml)
Description
measured with Luminex assay
Time Frame
measured after challenge with endotoxin at day 7 of medication
Title
concentration plasma MIP-1b(pg/ml)
Time Frame
measured after challenge with endotoxin at day 7 of medication
Title
concentration plasma IFNgamma(pg/ml)
Description
measured with Luminex assay
Time Frame
measured after challenge with endotoxin at day 7 of medication
Title
plasma adenosine
Time Frame
measured after challenge with endotoxin at day 7 of medication
Title
platelet monocyte complexes
Description
flowcytometric determination of monocytic load with platelets
Time Frame
measured after challenge with endotoxin at day 7 of medication
Title
platelet neutrophil complexes
Description
flowcytometric determination of neutrophil load with platelets
Time Frame
measured after challenge with endotoxin at day 7 of medication
Title
platelet reactivity
Description
ex vivo stimulation of platelets with ADP and collagen, response measured as P-selectin and fibrinogen)
Time Frame
measured after challenge with endotoxin at day 7 of medication
Title
monocytic tissue factor expression
Description
tissue factor expression on monocytes as measured by flow cytometry
Time Frame
measured after challenge with endotoxin at day 7 of medication
Title
monocytic HLA-DR expression
Description
as measured by flow cytometry
Time Frame
measured after challenge with endotoxin at day 7 of medication
Title
CD14/16 ratio
Description
measured with flow cytometry
Time Frame
measured after challenge with endotoxin at day 7 of medication
Title
platelet von Willebrandfactor expression
Description
measured with flow cytometry
Time Frame
measured after challenge with endotoxin at day 7 of medication
Title
VASP-P
Description
ELISA
Time Frame
difference between measurement prior to start of study drug after challenge with endotoxin at day 7 of medication
Title
symptoms during endotoxin day
Description
6 point likert scale
Time Frame
measured after challenge with endotoxin at day 7 of medication
Title
blood pressure
Description
mmHg
Time Frame
measured after challenge with endotoxin at day 7 of medication
Title
temperature
Description
tympanic temperature
Time Frame
measured after challenge with endotoxin at day 7 of medication

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 and ≤ 35 years Male No known current medical/psychiatric diseases Exclusion Criteria: History, signs or symptoms of any cardiovascular disease History of chronic obstructive pulmonary disease (COPD) or asthma History of hemorrhagic diathesis, or any other disorder associated with increased risk of bleeding Previous spontaneous vagal collapse Use of any medication Smoking Liver enzyme abnormalities (defined as ALAT and/or ASAT > twice upper limit of normality) Thrombocytopenia (<150*109 /ml) or anemia (haemoglobin < 8.0 mmol/L) Any obvious disease associated with immune deficiency Febrile illness in the week before the LPS challenge Hypersensitivity to ticagrelor or any excipients Active pathological bleeding History of intracranial haemorrhage History of dyspepsia quantitative bleeding assessment tool (BAT) score >3 (see Appendix 1) Participation in another drug trial or donation of blood 3 months prior, until 3 months after the planned LPS challenge Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrioventricular block, third degree atrioventricular block or a complex bundle branch block Hypertension (defined as RR systolic > 160 or RR diastolic > 90) Hypotension (defined as RR systolic < 100 or RR diastolic < 50) Renal impairment (defined as MDRD < 60 ml/min)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter Pickkers, MD, PhD
Organizational Affiliation
Radboud University Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Niels Riksen, MD, PhD
Organizational Affiliation
Radboud University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Intensive Care Medicine, Radboud University Nijmegen Medical Centre
City
Nijmegen
State/Province
Gelderland
ZIP/Postal Code
6500HB
Country
Netherlands

12. IPD Sharing Statement

Learn more about this trial

Ticagrelor in Human Endotoxemia Response to Human Endotoxemia

We'll reach out to this number within 24 hrs